Esperion Theraptc (ESPR) Stock Price, Quote & News

Company Profile

Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C) in the United States. The company's marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovasc...

Industry: Drug Manufacturers - Specialty & Generic

Sector: Healthcare

Phone: 734 887 3903

Website: www.esperion.com

Address:

3891 Ranchero Drive, Suite 150, Ann Arbor, United States

simbha Mar. 21 at 10:11 PM

$ESPR Weekly chart got reset nicely. However markets turmoil will continue with ongoing oil war. April will be even more ugly for markets. However ESPR will be bottom around 2.25 +/- 0.25. . Then rally will start when market bounce back. Fingers 🤞 crossed.

0 · Reply

meistermell Mar. 21 at 8:06 PM

$ESPR Agreed. They also had to launch into covid, with the collective plandemic induced mass hysteria shutting down life on planet earth as we know it over a simple cold this was extremely hard on small businesses, including small and mid cap biotechs. Crap happens, the time has come to rise to double digits. Thx for the .70s special

0 · Reply

no_lies_told Mar. 21 at 6:01 PM

$MNKD $ESPR Both seem to be siblings in excessive selloffs and both look very attractive for a short term flip. The market is giving some of us a gift here.

0 · Reply

SkywalkerAR Mar. 21 at 5:31 PM

$ESPR

0 · Reply

JasonZemanskyPhD Mar. 21 at 5:06 PM

$ESPR anyone made money and left are weak hands. And any one listened to this retard and kept holding are diamond hands . 😀 Because market is not for making money it is for falling in love with random companies and making friend with random nobodies .

1 · Reply

NEWBIGTECH Mar. 21 at 3:34 PM

$ESPR

0 · Reply

NEWBIGTECH Mar. 21 at 3:32 PM

$ESPR analysis of 22 #WallStreet analysts, $ESPR has a #bullish consensus with a median price target of $5.16 (ranging from $1.78 to $16.00). The overall analyst rating is Buy (7.7/10). Currently trading at $2.60, the median forecast implies a 98.5% upside.

0 · Reply

maxhappy Mar. 21 at 3:19 PM

$ESPR

1 · Reply

Bear0927 Mar. 21 at 2:54 PM

$ESPR Some Saturday morning leisure reading. This retrospective study in the Journal of Clinical Lipidology came out 10 days ago. The findings suggest that increased LpA levels in ACS patients post event led to more difficulty achieving the LDL<55 target. It was of interest to me because all 345 patients were on the triple oral therapy of Statin/EZE/BA. Overall, LDL was lowered by 59% (+/- 17%). 69% of patients achieved LDL<50, 79% achieved LDL<55. Diabetic patients were 2.7X more likely to achieve goal, which adds nicely to the recent AHA dyslipidemia guidelines for diabetic patients. https://www.lipidjournal.com/article/S1933-2874(26)00071-1/abstract

1 · Reply

JasonZemanskyPhD Mar. 21 at 2:50 PM

$ESPR because I m the only one who knows math. All other are on meth . That applies to to the moon kids who saw 4 and back You all Loved it at 4 , loving it at 2.50 you will love it at 1.7

0 · Reply

Esperion's Bempedoic Acid Receives Multiple Class 1 Recommendations in 2026 ACC/AHA Multisociety Guideline for Management of Dyslipidemia

Mar 10, 2026, 10:40 AM EDT - 11 days ago

Esperion Therapeutics, Inc. (ESPR) Q4 2025 Earnings Call Transcript

Mar 10, 2026, 6:00 AM EDT - 11 days ago

Esperion Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

Mar 3, 2026, 5:22 PM EST - 18 days ago

Esperion Therapeutics, Inc. (ESPR) M&A Call Transcript

Mar 3, 2026, 6:00 AM EST - 18 days ago

Esperion Therapeutics and Corstasis Therapeutics Announce Esperion's Definitive Agreement to Acquire Corstasis, Expanding Its Cardiovascular Franchise with Enbumyst™ (bumetanide nasal spray)

Feb 18, 2026, 8:00 AM EST - 4 weeks ago

Esperion to Participate in The 2026 Citizens Life Sciences Conference

Feb 17, 2026, 8:00 AM EST - 4 weeks ago

Esperion Reaches Settlement Agreement with Fifth ANDA Filer Not to Market Generic Version of NEXLETOL® (bempedoic acid) & NEXLIZET® (bempedoic acid & ezetimibe) Prior to April 19, 2040

Feb 11, 2026, 4:30 PM EST - 5 weeks ago

Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Jan 14, 2026, 7:35 PM EST - 2 months ago

Esperion Therapeutics, Inc. (ESPR) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Jan 11, 2026, 6:00 PM EST - 2 months ago

Esperion Provides Business Update at 44th Annual J.P. Morgan Healthcare Conference

Nov 20, 2025, 4:03 PM EST - 4 months ago

Esperion Therapeutics, Inc. (ESPR) Presents at Jefferies London Healthcare Conference 2025 Transcript

Nov 18, 2025, 7:00 AM EST - 4 months ago

Esperion Partner HLS Therapeutics Announces Approval of NILEMDO® for the Reduction of LDL-Cholesterol in Canadians at Risk of Cardiovascular Disease

Nov 12, 2025, 10:16 AM EST - 4 months ago

Wasatch Ultra Growth Fund Q3 2025 Top Contributors And Detractors

CCCC CWST INSP MNDY SITM

Nov 11, 2025, 9:31 PM EST - 4 months ago

Esperion Therapeutics, Inc. (ESPR) Discusses Breaking the Statin Intolerance Barrier and Closing the Care Gap in Cardiovascular Health Transcript

Nov 10, 2025, 7:24 AM EST - 4 months ago

Esperion Therapeutics: Still An Attractive Risk/Reward Narrative As The Earnings Clock Ticks Toward Profitability

Nov 6, 2025, 2:06 PM EST - 4 months ago

Esperion Therapeutics, Inc. (ESPR) Q3 2025 Earnings Call Transcript

Nov 4, 2025, 8:00 AM EST - 4 months ago

Esperion Appoints Industry Veteran John Harlow as Chief Commercial Officer

Oct 27, 2025, 8:00 AM EDT - 5 months ago

Esperion Announces New Analyses from CLEAR Outcomes to be Presented at the American Heart Association (AHA) Scientific Sessions 2025

Oct 8, 2025, 8:01 AM EDT - 5 months ago

Penguin Solutions Posts Q4 Earnings, Joins Esperion Therapeutics, Joby Aviation And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session

JOBY PENG

Oct 7, 2025, 9:29 PM EDT - 5 months ago

Esperion Announces Pricing of Public Offering of Common Stock

Oct 7, 2025, 4:01 PM EDT - 5 months ago

Esperion Announces Proposed Public Offering of Common Stock

Oct 3, 2025, 8:00 AM EDT - 6 months ago

Esperion Reaches Settlement Agreement with ANDA Filer, Dr. Reddy's Laboratories, Not to Market Generic Versions of NEXLETOL® (bempedoic acid) and NEXLIZET® (bempedoic acid and ezetimibe) Prior to April 19, 2040

Sep 19, 2025, 8:00 AM EDT - 6 months ago

Esperion Partner Otsuka Receives Regulatory Approval to Market NEXLETOL® in Japan for the Treatment of Hypercholesterolemia

Sep 7, 2025, 10:17 PM EDT - 6 months ago

Esperion Therapeutics, Inc. (ESPR) Presents At Cantor Global Healthcare Conference 2025 Transcript

Sep 5, 2025, 10:39 AM EDT - 7 months ago

Top 2 Health Care Stocks That May Plunge This Month

NUVB

Aug 29, 2025, 8:00 AM EDT - 7 months ago

Esperion's Bempedoic Acid Receives Level 1a Recommendation in Updated ESC/EAS Guidelines for Management of Dyslipidaemias

Aug 5, 2025, 10:10 AM EDT - 8 months ago

Esperion Therapeutics, Inc. (ESPR) Q2 2025 Earnings Call Transcript

Aug 5, 2025, 6:00 AM EDT - 8 months ago

Esperion Reports Second Quarter 2025 Financial Results and Provides Business Update

Jul 22, 2025, 8:00 AM EDT - 8 months ago

Esperion to Report Second Quarter 2025 Financial Results on August 5

Jul 1, 2025, 8:06 AM EDT - 9 months ago

Esperion Appoints Craig Thompson to Board of Directors

Jun 14, 2025, 7:03 AM EDT - 10 months ago

Can The Promise Of Profitability And Pipelines Sustain A Recovery For Esperion Therapeutics?

May 12, 2025, 8:00 AM EDT - 11 months ago

Esperion Reaches Settlement Agreement with ANDA Filer Not to Market Generic Version of NEXLETOL® (bempedoic acid) Prior to April 19, 2040

May 9, 2025, 8:00 AM EDT - 11 months ago

Esperion to Participate in H.C. Wainwright's 3rd Annual BioConnect Investor Conference

May 8, 2025, 6:30 AM EDT - 11 months ago

Esperion Partners with HLS Therapeutics to Commercialize NEXLETOL® (bempedoic acid) and NEXLIZET® (bempedoic acid and ezetimibe) in Canada

May 6, 2025, 10:49 AM EDT - 11 months ago

Esperion Therapeutics, Inc. (ESPR) Q1 2025 Earnings Call Transcript

Apr 25, 2025, 8:00 AM EDT - 11 months ago

Esperion to Participate in The Citizens Life Sciences Conference

Apr 24, 2025, 8:00 AM EDT - 11 months ago

Esperion Unveils Promising Research Supporting Lead Development Candidates for Primary Sclerosing Cholangitis (PSC) at R&D Day 2025

Apr 10, 2025, 8:00 AM EDT - 1 year ago

Esperion to Host R&D Day to Highlight Cardiometabolic Pipeline Innovation and Next-Generation Therapeutics on April 24, 2025

Apr 1, 2025, 8:00 AM EDT - 1 year ago

Esperion Appoints Robert E. Hoffman to Board of Directors

Mar 4, 2025, 10:34 AM EST - 1 year ago

Esperion Therapeutics, Inc. (ESPR) Q4 2024 Earnings Call Transcript

Mar 4, 2025, 6:00 AM EST - 1 year ago

Esperion Reports Fourth Quarter and Full Year 2024 Financial Results

Mar 3, 2025, 8:00 AM EST - 1 year ago

Esperion Partners with CSL Seqirus to Commercialize NEXLETOL® (bempedoic acid) and NEXLIZET® (bempedoic acid and ezetimibe) in Australia

Feb 18, 2025, 8:00 AM EST - 1 year ago

Esperion to Report Fourth Quarter and Full Year 2024 Financial Results on March 4

Dec 18, 2024, 7:00 AM EST - 1 year ago

Esperion Strengthens Balance Sheet with Closing of Significant Refinancing Transactions

Dec 14, 2024, 9:00 AM EST - 1 year ago

Undercovered Dozen: Ubiquiti, Ready Capital, Cardiff Oncology, Vodafone +

CRDF UI VOD DE FLNC GASS HII

Dec 13, 2024, 6:00 AM EST - 1 year ago

Esperion Announces $210 Million Convertible Debt Financing

Dec 12, 2024, 8:00 AM EST - 1 year ago

Esperion Partners with Neopharm to Commercialize NEXLETOL® (bempedoic acid) and NEXLIZET® (bempedoic acid and ezetimibe) in Israel

Dec 8, 2024, 7:43 AM EST - 1 year ago

Will The Long Awaited Breakout For Esperion Therapeutics Hold?

Nov 18, 2024, 10:30 AM EST - 1 year ago

Esperion Highlights New Exploratory Data from CLEAR Outcomes Trial Highlighting Value of NEXLETOL® (bempedoic acid) in Oral Featured Science Session and Multiple Poster Presentations at AHA Scientific Sessions 2024

Nov 13, 2024, 2:08 AM EST - 1 year ago

Esperion Therapeutics: Growth Initiatives Are Paying Off - Buy

simbha Mar. 21 at 10:11 PM

0 · Reply

meistermell Mar. 21 at 8:06 PM

0 · Reply

no_lies_told Mar. 21 at 6:01 PM

$MNKD $ESPR Both seem to be siblings in excessive selloffs and both look very attractive for a short term flip. The market is giving some of us a gift here.

0 · Reply

SkywalkerAR Mar. 21 at 5:31 PM

$ESPR

0 · Reply

JasonZemanskyPhD Mar. 21 at 5:06 PM

1 · Reply

NEWBIGTECH Mar. 21 at 3:34 PM

$ESPR

0 · Reply

NEWBIGTECH Mar. 21 at 3:32 PM

0 · Reply

maxhappy Mar. 21 at 3:19 PM

$ESPR

1 · Reply

Bear0927 Mar. 21 at 2:54 PM

1 · Reply

JasonZemanskyPhD Mar. 21 at 2:50 PM

$ESPR because I m the only one who knows math. All other are on meth . That applies to to the moon kids who saw 4 and back You all Loved it at 4 , loving it at 2.50 you will love it at 1.7

0 · Reply

Petey3163 Mar. 21 at 11:20 AM

$ESPR

1 · Reply

SkywalkerAR Mar. 21 at 10:56 AM

$ESPR Out of 8 analysts covering the stock, BofA is virtually the only one with a negative outlook (Underperform, PT $1.78), joined only by Weiss Ratings with a Sell. All the others — HC Wainwright, Piper Sandler, Cantor Fitzgerald, Citizens JMP, Citigroup — are Buy or Overweight with price targets between $5 and $16. BofA even maintained its bearish view after bempedoic acid received multiple Class 1 recommendations in the new 2026 ACC/AHA dyslipidemia guidelines. Until all the ongoing ANDA disputes are resolved, they can’t be considered completely wrong — but they are certainly a very lonely voice. https://www.investing.com/news/analyst-ratings/bofa-reiterates-esperion-therapeutics-stock-underperform-rating-93CH-4564249

2 · Reply

Albertowest Mar. 21 at 10:49 AM

$ESPR the case between Esperion and Sandoz is now heading into Markman (claim construction), only one term in dispute and this is what will ultimately define the outcome. Can a settlement happen before Markman? Yes and before or around that hearing, parts proposed May or June. It simply confirms that Sandoz is testing a specific legal angle, this is the real catalyst.

0 · Reply

biotech_expert Mar. 21 at 7:21 AM

$ESPR But was it one for the ages? And you failed to mention about the beautiful candle that was printed!

0 · Reply

HAGAKURE Mar. 21 at 6:10 AM

$ESPR

0 · Reply

omar_progressivetrading Mar. 21 at 2:48 AM

$ESPR — Another week, another day. Hold on to your pants, Moon Kids. Just like I predicted, many will abandon ship along the way. That’s the nature of this game. Weak hands chase noise. Strong hands understand the journey. Only the ones with conviction will remain when the real move begins. To The Moon & Beyond! 🫡 🌖

1 · Reply

Gary9912 Mar. 21 at 2:03 AM

$ESPR Positive take from an established cardiologist, Dimitri Richter on BA , he likes the drug, he mentions at the end of the video that BA will find its place as a useful tool in statin intolerance now because of the guidelines in Europe and here and he says it’s a better option with ezitimibe first over PCSK9 because it’s much cheaper. He also points out and we’ve heard before and ow again that in the clear outcomes trial, may more patients in the placebo group was receiving PCSK9 therapy because entire LDL remained high, which should have screwed the results leading to the final outcomes on BA being lessened. https://x.com/cardio_vumedi/status/2034978261713777112?s=46&t=0qGPcTfX8as0XYMijymapw

0 · Reply

augie0030 Mar. 21 at 12:36 AM

$ESPR lotta room for improvement

3 · Reply

Albertowest Mar. 20 at 10:30 PM

$ESPR and 760K at AH

0 · Reply

biotech_expert Mar. 20 at 9:38 PM

$ESPR Marching towards 7K scripts per week for Nexlizet. This does not include any scripts Rx'd by Kaiser assuming they are doing so. Kaiser does not report to Symphony. Week ending 3/13/2026 Nexletol TRx 6.XXk NRx 2.85k TRx Dollars $5.89MM Nexlizet Trx 6.XXk NRx 2.93k TRx Dollar $6.62MM

1 · Reply

OldManLogan Mar. 20 at 9:35 PM

$ESPR It's interesting from your numbers that even 0% weekly growth in Q2 fers you 10% quarterly growth and 1% weekly gets you to 19% quarterly growth... with all this in mind, I would suggest that 20% growth next quarter is basically a floor... I'm still going with $48M, $60M, $75M and $90M for the 4 quarters of 2026... I could be over a touch on Q1 and understand a bit on Q2... Cheers.

0 · Reply

BRLondon Mar. 20 at 8:38 PM

$ESPR considering the overall market it was a decent week, especially with the recent growth in scripts, before the guidelines and ACC presentation... As Dave said, we're going start Q2 from a good base, ready for the acceleration from guidelines and increased awareness. $60 M from US revenue alone in Q2 is achievable. Profitability is very close. LFG!

0 · Reply

Market Cap	643.31M
Revenue (ttm)	403.14M
Net Income (ttm)	-22.68M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	48.17
Profit Margin	-5.63%
Debt to Equity Ratio	-0.50

Volume	5,717,000
Avg Vol	5,068,776
Day's Range	N/A - N/A
Shares Out	256.81M
Stochastic %K	19%
Beta	1.11
Analysts	Sell
Price Target	$6.97